Neuromuscular

The National Institutes of Health program, dubbed Accelerating Leading-edge Science in ALS, or ALS2, is set to invest $25M over 5 years for exceptionally creative and riskier research.

One of the first case-series studies that analyzed children with COVID-19 suggest that SARS-CoV-2 should be considered for differential diagnosis in children presenting with new neurologic symptoms and splenium signal changes on MRI.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 3, 2020.

In the wake of the COVID-19 pandemic, health care providers and patients have had to quickly adapt to new formats of care models to promote safety while retaining care standards.

Biohaven’s verdiperstat has entered a phase 3 trial for the treatment of multiple system atrophy, with a new drug application submission on the agenda for late 2021.

The sBLA for onabotulinumtoxinA is supported by the findings from a randomized, double-blind phase 3 study evaluating the safety and efficacy of onabotulinumtoxinA in more than 100 pediatric patients.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 26, 2020.

Preliminary results showed that SRP-9001 is associated with clinically meaningful improvement that is greater than that observed with standard-of-care treatment, including corticosteroids.

The data, from the phase 3 COMET trial, will be the basis for global regulatory submissions in the second half of 2020, according to manufacturer Sanofi.

Neurology News Network for the week ending June 20, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 19, 2020.

Preliminary 12-month data from the JEWELFISH study in previously treated patients showed rapid and sustained increases in survival motor neuron protein levels.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 12, 2020.

The new data from the phase 2 NURTURE study are set to be presented at the virtual Cure SMA Research and Clinical Care Meeting.

The funding for the Pediatric Neuromuscular Clinical Research Network will provide assistance to some of the world's highly skilled clinical trial investigators who have led studies that have resulted in numerous FDA approvals of breakthrough treatments.

Data show the therapy’s positive safety and expression results from a small number of clinical trial participants with limb-girdle muscular dystrophy type 2E out to 1 year.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 5, 2020.

The Nippon Shinkyaku therapy also showed no treatment-emergent adverse events that required reduction, interruption, or discontinuation of the treatment.

Topline results from the phase 3 trial of arimoclomol are expected to be announced in the first half of 2021.

The agent’s developer, Argenx, stated that it plans on submitting a biologics license application (BLA) to the FDA by the end of 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 29, 2020.